It is now 12 years since publication of the original Durban classification criteria for juvenile idiopathic arthritis (J. Rheumatol. 1998;25:1991-4) and 9 years since the revision in Edmonton (J. Rheumatol. 2004;31:390-2 ). Yet the majority of adult rheumatologists, the public, and even many pediatric rheumatologists continue to believe that the new criteria simply substituted an I for an R (JIA instead of JRA) to emphasize that most childhood arthritis is not related to the rheumatoid...

NEW YORK (EGMN) – Rituximab may offer an alternative treatment for children whose juvenile dermatomyositis does not respond to available therapies, depending on the outcome of an ongoing trial, Dr. B. Anne Eberhard said at a meeting sponsored by New York University.There are no U.S. Food and Drug Administration–approved medications for juvenile dermatomyositis (JDM).The RIM (Rituximab in Myositis) trial is a randomized, phase II, placebo-phase controlled, multicenter trial investigating the...